about
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1.BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis.Conformational switching of the pseudokinase domain promotes human MLKL tetramerization and cell death by necroptosis.Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical useStrategies, Setbacks, and Successes in the Synthesis of (-)-SpiroleucettadineA small molecule interacts with VDAC2 to block mouse BAK-driven apoptosisStructures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutationsMLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis
P50
Q47741752-B598657F-FD88-4707-9228-A179D0D50631Q48139370-7ADF6FAD-E27B-4A66-B1EA-22165CA69CE8Q50422242-3C380F7C-D69D-499F-9ADE-C0CD091AE5E4Q55392555-03A67238-8B08-4367-A354-062FFEDDDC3BQ62817575-106AB5D3-5771-4C62-8A6E-3CE2A16D872FQ90022898-0D546B3A-B22B-4B1E-B425-3B597A31CB8EQ90576291-AD801BF5-A696-4FD3-9A72-0DA84E0DD4B6Q92501889-43A21FDB-4E6B-4A33-8369-D96DC7CD2DF0Q96609364-F246FAFC-9DA4-47B6-A1A6-7EE3CFC8BA73
P50
description
researcher
@en
name
Guillaume Lessene
@en
type
label
Guillaume Lessene
@en
prefLabel
Guillaume Lessene
@en
P31
P496
0000-0002-1193-8147